← All trials
NCT00741403
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2008
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 39
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Rafael Pharmaceuticals Inc.Lead sponsor
- British Columbia Cancer AgencyOverall official - principal investigator
- Eastchester Center for Cancer CareOverall official - principal investigator
- Pivotal Research CentersOverall official - principal investigator
- Mary Crowley Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.